Table 1. Participants' characteristics of with and without acquired hemophilia A for the baseline period.

Variable	Category	AHA (N = 34)	no AHA (N = 1,160,877)	P-value
Age		78.0 ± 9.4	73.8 ± 8.6	0.004
Age	60 - 69	9 (26.5)	456,548 (39.3)	0.002
	70 - 79	7 (20.6)	439,753 (37.0)	
	≧80	18 (52.9)	274,576 (23.7)	
Sex	Men	18 (52.9)	508,563 (43.8)	0.286
Without any comorbidities		**6 (17.7)**	**451,709 (38.9)**	**0.007**
Comorbidities (Charlson)				
Cerebrovascular disease	Presence	10 (29.4)	217,309 (18.7)	0.168
Any malignancy	Presence	4 (11.8)	117,197 (10.1)	0.969
Dementia	**Presence**	**6 (17.7)**	**61,565 (5.3)**	**0.005**
AIDS / HIV	Presence	0	135 (0.0)	1.000
Myocardial infarction	Presence	3 (8.8)	28,754 (2.5)	0.067
Renal disease	Presence	2 (5.9)	43,523 (3.8)	0.839
Congestive heart failure	**Presence**	**10 (29.4)**	**156,058 (13.4)**	**0.013**
Peripheral vascular disease	**Presence**	**8 (23.5)**	**128,202 (11.0)**	**0.040**
Chronic pulmonary disease	Presence	4 (11.8)	228,647 (19.7)	0.344
Rheumatic disease	**Presence**	**5 (14.7)**	**35,546 (3.1)**	**0.001**
Peptic ulcer disease	Presence	9 (26.5)	218,404 (18.8)	0.356
Liver disease (mild)	Presence	5 (14.7)	172,724 (14.9)	1.000
Liver disease (moderate or severe)	Presence	0	3,915 (0.3)	1.000
Diabetes mellitus without chronic complications	Presence	3 (8.8)	27,596 (2.4)	0.057
Diabetes mellitus with chronic complications	Presence	2 (5.9)	69,439 (6.0)	1.000
Hemiplegia or paraplegia	Presence	0	14,950 (1.3)	1.000
Metastatic solid tumor	Presence	2 (5.9)	15,665 (1.6)	0.122

Other comorbidities

Alzheimer's disease	**Presence**	**6 (17.7)**	**46,554 (4.0)**	**<0.001**
Skin disease*	Presence	0	8,257 (0.7)	1.000

AHA, acquired hemophilia A; AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus. The bold type indicates statistical significance. *Skin diseases include pemphigus, epidermolysis bullosa, erythema annulare centrifugum, erythema multiforme, exfoliative dermatitis and psoriasis.

Table 2. Univariate Cox Regression Hazards Analysis for incidence of acquired hemophilia A.

Variable (reference)	Category	HR	95%CI	P-value
Age (60-69 years)	70-79 years	0.81	0.30-2.16	0.668
	>80 years	**3.64**	**1.64-8.11**	**0.002**
Sex (vs. men)	Women	0.63	0.32-1.23	0.178
Comorbidities by Charlson (absence)				
Cerebrovascular disease	Presence	1.96	0.94-4.10	0.074
Any malignancy	Presence	1.37	0.48-3.89	0.555
Dementia	**Presence**	**5.34**	**2.21-12.94**	**<0.001**
AIDS / HIV	Presence	NE	NE	NE
Myocardial infarction	**Presence**	**4.35**	**1.33-14.25**	**0.015**
Renal disease	Presence	2.03	0.49-8.50	0.330
Congestive heart failure	**Presence**	**3.17**	**1.51-6.63**	**0.002**
Peripheral vascular disease	**Presence**	**2.53**	**1.14-5.58**	**0.022**
Chronic pulmonary disease	Presence	0.57	0.20-1.62	0.293
Rheumatic disease	**Presence**	**5.62**	**2.17-14.51**	**<0.001**
Peptic ulcer disease	Presence	1.59	0.74-3.41	0.232
Liver disease (mild)	Presence	1.00	0.39-2.58	0.996
Liver disease (moderate or severe)	Presence	NE	NE	NE
Diabetes mellitus without chronic complications	**Presence**	**4.78**	**1.46-15.64**	**0.010**
Diabetes mellitus with chronic complications	Presence	1.03	0.25-4.30	0.968
Hemiplegia or paraplegia	Presence	NE	NE	NE
Metastatic solid tumor	**Presence**	**7.24**	**1.73-30.25**	**0.007**
Other comorbidities				
Alzheimer's disease	**Presence**	**6.72**	**2.78-16.28**	**<0.001**
Skin disease*	Presence	NE	NE	NE
Medications				
All antibiotics	Presence	1.97	0.97-3.98	0.059
Aminoglycosides	Presence	2.61	0.92-7.40	0.072
All beta-lactam antibiotics	Presence	1.91	0.98-3.75	0.059
Penicillin	Presence	2.10	0.64-6.87	0.220

Cephalosporins	Presence	1.51	0.76-3.02	0.241
Carbapenems	**Presence**	**12.31**	**3.76-40.30**	**<0.001**
Other beta-lactam antibiotics	Presence	NE	NE	NE
Chloramphenicol	Presence	NE	NE	NE
Fosfomycin	Presence	2.19	0.30-16.05	0.439
Glycopeptides	**Presence**	**21.55**	**2.94-157.76**	**0.003**
Macrolides	Presence	1.52	0.69-3.37	0.297
Tetracyclines	Presence	2.41	0.33-17.62	0.386
Quinolones	Presence	1.30	0.57-2.99	0.534
Sulfa drugs	Presence	4.36	0.60-31.92	0.147
Other antibiotics	Presence	NE	NE	NE
Amiodarone	Presence	NE	NE	NE
Antifungal drugs	Presence	NE	NE	NE
All antihypertensive drugs	Presence	1.66	0.84-3.29	0.144
ACE inhibitors	Presence	NE	NE	NE
ARBs	Presence	1.23	0.60-2.52	0.577
CCBs	Presence	1.77	0.91-3.47	0.095
DRIs	Presence	NE	NE	NE
Clopidogrel	Presence	1.01	0.14-7.37	0.994
Diuretics	Presence	1.02	0.31-3.35	0.971
Antidiabetic drugs	Presence	0.76	0.23-2.48	0.649
Fludarabine	Presence	NE	NE	NE
Heparin	Presence	2.03	0.62-6.63	0.243
All anticonvulsants	Presence	1.35	0.18-9.87	0.768
Phenytoin	**Presence**	**12.95**	**1.77-94.75**	**0.012**
Phenytoin (prodrug)	Presence	NE	NE	NE
All antidementia drugs	**Presence**	**4.98**	**1.75-14.15**	**0.003**
Donepezil	**Presence**	**4.78**	**1.46-15.65**	**0.010**
Galanthamine	Presence	NE	NE	NE
Memantine	Presence	5.99	0.82-43.87	0.078
Rivastigmine	Presence	NE	NE	NE

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; DRI, direct renin inhibitor; HR, hazard ratio; NE, not

estimated. The bold type indicates statistical significance. *Skin diseases include pemphigus, epidermolysis bullosa, erythema annulare centrifugum, erythema multiforme, exfoliative dermatitis and psoriasis.

Table 3. Multivariable Cox regression analysis for incidence of acquired hemophilia A.

Variable	HR	95%CI	*P*-value
Age	1.04	1.00-1.09	0.067
Alzheimer's disease	**4.28**	**1.67-10.97**	**0.002**
Congestive heart failure	1.95	0.90-4.28	0.092
Peripheral vascular disease	1.78	0.79-4.01	0.166
Rheumatic disease	**4.65**	**1.79-12.12**	**0.002**

The HR is for presence of the risk factor and for one year of age.

CI, confidence interval; HR, hazard ratio. The bold type indicates statistical significance. Alzheimer's disease and rheumatic disease were identified as risk factors for acquired hemophilia A.

Table 4. Treatment among patients with acquired hemophilia A.

Treatment	Number of AHA patients (%) N=34
Immunosuppressive agent	32 (94.1)
Steroids alone	27 (79.4)
Steroids and cyclophosphamide	5 (14.7)
Bypassing treatment	10 (29.4)
Recombinant activated Factor Ⅶ	7 (20.6)
Plasma-derived activated prothrombin complex concentrate	6 (17.6)
Transfusion	12 (34.3)

AHA, acquired hemophilia A.